Research Studies and Clinical Trials Search
Results
Acute Leukemia or Myelodysplastic Syndrome: A study comparing matched unrelated donor versus haploidentical related myeloablative hematopoietic cell transplantation
This study is for children and young adults: -Ages 6 months to 21 years old -With a diagnosis of acute leukemia or myelodysplastic syndrome (MDS)...
This study is for children and young adults: -Ages 6 months to 21 years old -With a diagnosis of acute leukemia or myelodysplastic syndrome (MDS) This study is being done to learn more about hematopoietic cell transplantation (HCT) that use mismatched related donor (haploidentical or haplo) versus a matched unrelated donor (MUD). The research team will use bone marrow or stem cells from a mismatched related family donor or from a MUD and then compare the transplant results.
Acute Lymphoblastic Leukemia or Lymphoma (ALL): A study on premedicating pediatric patients receiving PEG-asparaginase with antihistamines
Patients who are ages 1 to 26 may be eligible for this study. The purpose of this study is to see if taking an antihistamine (Benadryl® and either Pepcid® or Tagamet®) before PEG-asparaginase reduces allergic reactions. We also want to see if it reduces the need to switch to...
Patients who are ages 1 to 26 may be eligible for this study. The purpose of this study is to see if taking an antihistamine (Benadryl® and either Pepcid® or Tagamet®) before PEG-asparaginase reduces allergic reactions. We also want to see if it reduces the need to switch to Erwinia asparaginase or another PEG-asparaginase substitute. In this study, we will document any side effects that occur within 30 days of treatment with PEG-asparaginase. We will also look at the level of asparaginase in patients' blood after each dose. We may also look at patients' genetic information to see how the body reacts to treatment with PEG-asparaginase.
Acute Myeloid Leukemia (AML): A clinical study of enasidenib to treat relapsed/refractory AML with IDH-2 mutations
The overall goal of this study is to find out what effects, good and/or bad, enasidenib has on children and adolescents with AML with IDH2 mutations. This study is for patients who are 2 to 18 years old.
The overall goal of this study is to find out what effects, good and/or bad, enasidenib has on children and adolescents with AML with IDH2 mutations. This study is for patients who are 2 to 18 years old.
B-Cell Acute Lymphoblastic Leukemia (B-ALL): A clinical trial to study inotuzumab ozogamicin (InO) in combination with chemotherapy in children and young adults with relapsed or refractory B-ALL
The overall goal of this study is to find out what effect, good and/or bad, the medicine inotuzumab ozogamicin (InO) in combination with chemotherapy has on children and young adults with relapsed or refractory B-ALL. The treatment used in this study involves cancer fighting...
The overall goal of this study is to find out what effect, good and/or bad, the medicine inotuzumab ozogamicin (InO) in combination with chemotherapy has on children and young adults with relapsed or refractory B-ALL. The treatment used in this study involves cancer fighting medicine called chemotherapy plus the medicine InO. The treatment on this study takes about 2 months, divided into 2 phases of therapy. Patients must be ≥1 year and < 22 years of age at the time of enrollment.
B-Cell Acute Lymphoblastic Leukemia (B-ALL): A study eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults
There are two groups involved in this study, Observational and Treatment. Patients of any age diagnosed with B-Cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), or Mixed phenotype acute leukemia (MPAL) may join the Observational group. B-ALL...
There are two groups involved in this study, Observational and Treatment. Patients of any age diagnosed with B-Cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), or Mixed phenotype acute leukemia (MPAL) may join the Observational group. B-ALL patients 1 to 31 years of age requiring hematopoietic cell transplantation and NGS-MRD negative may join the Treatment group. In this study, researchers would like to see if not giving patients total body irradiation (also called TBI) therapy before transplant is as good as giving patients radiation before transplant.
B-cell acute lymphoblastic leukemia (B-ALL): A study of blinatumomab added to standard chemotherapy in patients with or without down syndrome
This study is available for patients ages 1 to 10 with B-ALL. Those ages 1 to 31 with down syndrome and B-ALL are eligible to participate. Patients with B-LLy (with or without down sydrome) and are 1 to 31 years old are also eligible. In this study, we will collect information...
This study is available for patients ages 1 to 10 with B-ALL. Those ages 1 to 31 with down syndrome and B-ALL are eligible to participate. Patients with B-LLy (with or without down sydrome) and are 1 to 31 years old are also eligible. In this study, we will collect information about participants' leukemia and their response to Induction therapy. We will also compare the effects, good and/or bad, of blinatumomab when added to standard chemotherapy.
B-cell acute lymphoblastic leukemia (B-ALL): A study on cell therapy medication to treat cancer cells and prevent relapse
This study is for individuals between 1 year of age and 25 years of age who have been diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). It involves children or young adults who have recently started receiving cancer treatment for the first time and have a small number...
This study is for individuals between 1 year of age and 25 years of age who have been diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). It involves children or young adults who have recently started receiving cancer treatment for the first time and have a small number of cancer cells still detected in their bodies after the first part of treatment. When these small number of cancer cells are present after the induction and consolidation treatment phases (initial months of treatment) for B-ALL, the patients are considered to be in a high risk group. This means their cancer is harder to treat and may be more likely to return after treatment. The goal of this study is to see if a specific type of cell therapy medication may treat the remaining small amount of cancer cells and help prevent relapse in children and young adults who are part of this high-risk group.
Bone Cancer: A study comparing two surgery methods to treat cancer in the lung
This study is for: • Patients less than 50 years old • Who have osteosarcoma (OST), a type of bone cancer, that has spread into the lungs...
This study is for: • Patients less than 50 years old • Who have osteosarcoma (OST), a type of bone cancer, that has spread into the lungs The overall goal of this study is to compare the effects, good and/or bad, of two different surgery methods to find out which is better. The two types of surgeries are called open thoracic surgery and thoracoscopy. Study patients will be randomly assigned to one of the two types of surgery.
Brain Tumors: A study to see if memantine protects the brain during radiation therapy treatment in children
This study is for: • Patients ages 4 to 18 • Who have been diagnosed with a brain tumor...
This study is for: • Patients ages 4 to 18 • Who have been diagnosed with a brain tumor The goal of this study is to see if the drug memantine makes a difference in changes to attention, memory, or other thought processes (called cognitive function changes) in children and adolescents treated with radiation therapy for a brain tumor. In this study participants will get 1 of 2 treatments: memantine (active drug) or placebo (no active drug). The treatment (memantine or placebo) participants receive is decided by a process called randomization, which means that the treatment is assigned based on chance like flipping a coin. Participants will also complete questionnaires and short computer testing sessions.
Cancer - Solid or CNS Tumors: A clinical study of sirolimus and metronomic chemotherapy for recurrent and/or refractory tumors
This is a study of a drug called sirolimus. Sirolimus has not been approved for use by the FDA for this use and is considered an investigational drug. "Investigational" means that it is still experimental because it has not been tested for use for the treatment of solid or CNS...
This is a study of a drug called sirolimus. Sirolimus has not been approved for use by the FDA for this use and is considered an investigational drug. "Investigational" means that it is still experimental because it has not been tested for use for the treatment of solid or CNS tumors. In this study, sirolimus is given in combination with other chemotherapy drugs. The drugs etoposide, cyclophosphamide and celecoxib are used in combination in children with your type of cancer when it returns or stops responding to treatment. When this combination of etoposide, cyclophosphamide and celecoxib is given by mouth, at lower doses than given through the vein, it is much better tolerated by patients. It also helps stop tumor growth by preventing blood from getting to the tumor. Blood supply is needed for tumors to grow. In this study, sirolimus is added to these three drugs. Study doctors want to learn if patients can tolerate this. They also want to learn whether it improves the effect that this therapy has on tumor growth.
Cancer or Cancer Related Illness: Blood and/or tissue samples collected and stored for future research
Patients with a suspected or confirmed oncology or bone marrow failure diagnosis are eligible to participate. If enrolled, blood and/or tissue samples will be collected, deidentified, and stored for use in future research projects. De-identified clinical data will also be...
Patients with a suspected or confirmed oncology or bone marrow failure diagnosis are eligible to participate. If enrolled, blood and/or tissue samples will be collected, deidentified, and stored for use in future research projects. De-identified clinical data will also be collected for future research.
Cancer with ALK or ROS1 mutations: A study of ensartinib as treatment for tumors
This study is for children, adolescents, and young adults who: • Are 12 months – 21 years old • Have cancers that are not responding to therapy, or have come back, and also have ALK or ROS1 gene mutations • Are able to swallow pills...
This study is for children, adolescents, and young adults who: • Are 12 months – 21 years old • Have cancers that are not responding to therapy, or have come back, and also have ALK or ROS1 gene mutations • Are able to swallow pills The medicine, ensartinib, has been shown to block the growth of cancer cells with ALK or ROS1 in laboratory experiments. Early studies with ensartinib have been conducted in adults. The study drug is taken by mouth for up to 24 months. The goal of this study is to find what effects ensartinib has on a child's tumor, any side effects it may cause, and to learn more about the pharmacology of the medication.
Cancer: A study screening for genetic changes (mutations) that may respond to specific drug therapies for tumors
The main purpose of this study is to learn how well tumors that have specific genetic changes (mutations) respond to drugs that "target" those changes. This combination of a tumor with a mutation and a drug that aims at that mutation is called a "match."
The main purpose of this study is to learn how well tumors that have specific genetic changes (mutations) respond to drugs that "target" those changes. This combination of a tumor with a mutation and a drug that aims at that mutation is called a "match."
Cancer: An informational registry and tissue/blood storage bank for future research
This study is available for those who are 25 years old or younger. The goal of this study is to find better ways to diagnose, treat and prevent cancers in children, adolescents and young adults. We will collect some information about each participant's cancer and treatment. We...
This study is available for those who are 25 years old or younger. The goal of this study is to find better ways to diagnose, treat and prevent cancers in children, adolescents and young adults. We will collect some information about each participant's cancer and treatment. We will also collect extra tumor, blood, bone marrow, or other tissue from procedures done by doctors to help make a diagnosis and learn more about different cancers now and in the future.
Chemotherapy-induced vomiting: A study of Olanzapine in children receiving chemotherapy for Hematopoietic Stem Cell Transplant conditioning
Patients 2.5 to 18 years of age and are about to receive chemotherapy before a blood or bone marrow transplant may join this study. Chemotherapy drugs are used to prepare children for blood or bone marrow transplant. A few of the side effects of these drugs are nausea and...
Patients 2.5 to 18 years of age and are about to receive chemotherapy before a blood or bone marrow transplant may join this study. Chemotherapy drugs are used to prepare children for blood or bone marrow transplant. A few of the side effects of these drugs are nausea and vomiting. The purpose of this research study is to find out whether adding the drug olanzapine to standard antiemetics (drugs that help prevent vomiting) will be helpful in controlling chemotherapy-induced vomiting (CINV). To find this out, some of the participants in this study will receive olanzapine and others will receive a placebo (a substance that looks like olanzapine but does not have any active or medicinal ingredients). This will allow us to compare treatment of CINV with and without olanzapine.
Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG): A study of Selinexor with Radiation Therapy
This study is for children and young adults: -Ages 12 months to 21 years old -With a new diagnosis of high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)...
This study is for children and young adults: -Ages 12 months to 21 years old -With a new diagnosis of high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). This study is being done to find the highest and safest dose of selinexor with radiation therapy.
Germ Cell Tumors (GCT): A study comparing accelerated versus standard chemotherapy
Patients who are ages 11 to 45 years with germ cell tumors (GCT) may be eligible to participate in this study. In this study, researchers want to determine whether accelerated BEP (standard chemotherapy drugs Bleomycin, Etoposide, and cisPlatin) will be effective and well...
Patients who are ages 11 to 45 years with germ cell tumors (GCT) may be eligible to participate in this study. In this study, researchers want to determine whether accelerated BEP (standard chemotherapy drugs Bleomycin, Etoposide, and cisPlatin) will be effective and well-tolerated for patients with advanced GCTs. Researchers don't know yet if accelerated treatment is helpful in advanced GCTs and are hoping this study will answer that question.
Germ Cell Tumors (GCT): Monitoring patients with low risk GCT and using the drug carboplatin instead of cisplatin for patients with standard risk GCT.
Eligible patients must be diagnosed with having a germ cell tumor (GCT). Patients who are diagnosed with Stage I GCT may be eligible no matter the age. Those ages 0-25 who are diagnosed with Stage II-IV may be eligible depending on the location of the GCT. Researchers want to see...
Eligible patients must be diagnosed with having a germ cell tumor (GCT). Patients who are diagnosed with Stage I GCT may be eligible no matter the age. Those ages 0-25 who are diagnosed with Stage II-IV may be eligible depending on the location of the GCT. Researchers want to see if monitoring patients with low risk germ cell tumors after their tumor is removed is as effective as following surgery with chemotherapy and/or more surgery. Researchers also want to compare the effects of carboplatin with cisplatin on patients with standard risk germ cell tumors to find out which is better.
High Risk Medulloblastoma: A clinical study of elfornithine/DFMO as maintenance therapy after standard treatment
The purpose of this research study is to see how well the investigational drug, eflornithine HCl (DFMO) works for Medulloblastoma. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the ability of this...
The purpose of this research study is to see how well the investigational drug, eflornithine HCl (DFMO) works for Medulloblastoma. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the ability of this study drug to either keep the tumors in remission or, if for active tumors, for the tumors to respond to the treatment. It will also look at the safety and tolerability of DFMO.
High Risk Rhabdomyosarcoma: A Study to Compare Early Use of Vinorelbine and Maintenance Therapy
This study is available for those 50 years old or younger who have been diagnosed with high-risk rhabdomyosarcoma (HR-RMS), a type of cancer that occurs in the soft tissues of the body like the muscles. This study looks at how well two different chemotherapy regimens work when...
This study is available for those 50 years old or younger who have been diagnosed with high-risk rhabdomyosarcoma (HR-RMS), a type of cancer that occurs in the soft tissues of the body like the muscles. This study looks at how well two different chemotherapy regimens work when given to children and adults with HR-RMS disease. Adding vinorelbine to one of the chemotherapy regimens is experimental because it has not yet been proven to work for those with HR-RMS. A computer will be assigning which treatment plan study participants will receive. This is called randomization. We also want to find out if we can improve the outcome for participants by extending the traditional treatment to include a treatment phase called maintenance therapy. All participants will receive maintenance therapy.
High-grade Glioma (HGG) with BRAFV600-mutation: A clinical trial of dabrafenib and trametinib after radiation therapy
This study is for: • People who are ages 3 through 21 • Who are newly diagnosed with high-grade glioma...
This study is for: • People who are ages 3 through 21 • Who are newly diagnosed with high-grade glioma (HGG) with BRAFV600-mutation High-grade gliomas (HGGs) are hard to treat successfully. Two drugs that will be used in this study are dabrafenib and trametinib. This study will look at how well the combination of dabrafenib and trametinib works when given to children and young adults with HGGs after they receive radiation therapy. The use of this combination to treat pediatric brain tumors is experimental.
High-Risk Neuroblastoma (NBL): A study of immunotherapy with or without DFMO after molecular therapy and induction chemotherapy in newly diagnosed patients
In this study the team is testing the effectiveness of adding an experimental agent called DFMO to the standard immunotherapy for high-risk neuroblastoma. This portion of the study will be a randomized trial (like flipping a coin). The study team will use a computer system to...
In this study the team is testing the effectiveness of adding an experimental agent called DFMO to the standard immunotherapy for high-risk neuroblastoma. This portion of the study will be a randomized trial (like flipping a coin). The study team will use a computer system to randomly decide which group each study participant will be placed in. The participant's physicians will not be able to help decide which group they will be placed in. Half of subjects, Group A, will receive standard immunotherapy with Dinutuximab, GM-CSF, and Isotretinoin. The other half of subjects, Group B, will receive standard immunotherapy with Dinutuximab, GM-CSF, Isotretinoin in combination with the study drug DFMO. The study team cannot guarantee which group each participant will be placed in. At the end of the 6 cycles of immunotherapy, all patients (both Arm A and Arm B) will receive DFMO twice a day for 730 days as maintenance therapy.
Leukemia (B-cell acute lymphoblastic leukemia (B-ALL), Mixed Phenotype Acute Leukemia (MPAL), and B-Lly: A clinical trial adding study treatment to standard treatment
Those who are ages 1 to 25 and diagnosed with High Risk B-ALL, MPAL, or B-LLy are eligible to join this study. We would like to collect information about participants' leukemia and the effects of the first two phases of treatment, called Induction and Consolidation. For those...
Those who are ages 1 to 25 and diagnosed with High Risk B-ALL, MPAL, or B-LLy are eligible to join this study. We would like to collect information about participants' leukemia and the effects of the first two phases of treatment, called Induction and Consolidation. For those diagnosed with High Risk B-ALL, we would like to see if adding inotuzumab ozogamicin to standard chemotherapy maintains or improves outcomes. For those diagnosed with MPAL, we would like to determine the outcomes to treatment using High Risk B-ALL therapy. For those diagnosed with B-LLy, we would like to determine the outcomes to treatment using High Risk B-ALL therapy.
Low-Grade Glioma: A Study of the Drugs Selumetinib vs. Carboplatin/Vincristine
Study participants must be ages 2 through 21 and newly diagnosed or Previously Untreated Low-Grade Glioma (LGG). In this study, researchers want to if selumetinib works just as well as the standard treatment using carboplatin and vincristine (called CV) for patients with LGG...
Study participants must be ages 2 through 21 and newly diagnosed or Previously Untreated Low-Grade Glioma (LGG). In this study, researchers want to if selumetinib works just as well as the standard treatment using carboplatin and vincristine (called CV) for patients with LGG. Selumetinib is a drug that works by blocking a protein (a basic building block of the human body) that lets cancer cells grow without stopping. Early studies have shown that selumetinib was successful in treating patients with LGG that came back after a first attempt at treatment. However, the use of selumetinib in patients with previously-untreated LGG is considered experimental because selumetinib has not yet been FDA approved for this type of cancer.
Neuroblastoma: A clinical trial of elfornithine/DFMO and etoposide for relapsed/refractory neuroblastoma
The purpose of this research study is to evaluate the investigational drug eflornithine HCl (DFMO) along with etoposide for Neuroblastoma. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). Currently there are no standard of...
The purpose of this research study is to evaluate the investigational drug eflornithine HCl (DFMO) along with etoposide for Neuroblastoma. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). Currently there are no standard of care treatments for patients with neuroblastoma in remission or with relapsed/refractory neuroblastoma. This study will look at the ability of this study drug to either keep the tumors in remission or, if for active tumors, for the tumors to respond to the treatment. The study will also look at the safety and tolerability of DFMO.
Neuroblastoma: A study of DFMO as maintenance therapy
The purpose of this research study is to evaluate the investigational drug eflornithine HCl (DFMO) for neuroblastoma that is in remission (cured according to medical tests). An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA)...
The purpose of this research study is to evaluate the investigational drug eflornithine HCl (DFMO) for neuroblastoma that is in remission (cured according to medical tests). An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the ability of this study drug to keep tumors in remission and will also look at the safety and tolerability of DFMO.
Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) in Children: A study of selumetinib versus standard treatment
Study participants must be ages 2 through 21, and have been diagnosed with Neurofibromatosis type 1 (NF1) and a cancer called low-grade glioma (LGG). In this study, researchers would like to see if a drug called Selumetinib works just as well as the standard treatment for NF1...
Study participants must be ages 2 through 21, and have been diagnosed with Neurofibromatosis type 1 (NF1) and a cancer called low-grade glioma (LGG). In this study, researchers would like to see if a drug called Selumetinib works just as well as the standard treatment for NF1-associated LGG. Researchers would also like to see if selumetinib is better than the standard treatment in improving vision. Selumetinib is a drug that works by blocking proteins (a basic building block of the human body) needed for cell growth and killing cancer cells. The use of selumetinib in the treatment of previously untreated NF1-associated LGG is considered experimental because selumetinib has not yet been FDA approved for this type of cancer.
NGGCT Brain Cancer (Non-Germinomatous Central Nervous System Germ Cell Tumor): A clinical trial of radiation therapy compared to standard treatment
This clinical study is available for those ages 3 to 30 who have been diagnosed with a type of brain cancer called NGGCT and your tumor is "localized". The term localized means that the tumor has not spread to other parts of your brain or body. One goal for this study is to see...
This clinical study is available for those ages 3 to 30 who have been diagnosed with a type of brain cancer called NGGCT and your tumor is "localized". The term localized means that the tumor has not spread to other parts of your brain or body. One goal for this study is to see if treatment with RT to the spine and a portion of the brain works just as well as the standard treatment for people with localized NGGCT whose disease responds well to induction chemotherapy, or who have no signs of disease following surgery. The other goal is to see if we can lower the number of relapses in the spine for patients who receive RT to the spine and a portion of the brain, as compared to patients on previous studies who received RT to a portion of the brain only. Treatment is divided into 2 phases of therapy. In the first phase, participants will receive induction chemotherapy. In the second phase, participants will receive RT or additional chemotherapy plus RT. Some people on this study will also have surgery before the second phase of treatment to remove any tumor that remains after the first phase of treatment.
Ph+ ALL: A study of adding Imatinib to two different chemotherapy treatments in Children and Young Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
This study is available for those who are 1 through 21 and have been diagnosed with a form of Acute Lymphoblastic Leukemia (ALL) called Philadelphia chromosome positive (Ph+) ALL or ABL-class fusion positive ALL. The overall goal of this study is to determine if using a less...
This study is available for those who are 1 through 21 and have been diagnosed with a form of Acute Lymphoblastic Leukemia (ALL) called Philadelphia chromosome positive (Ph+) ALL or ABL-class fusion positive ALL. The overall goal of this study is to determine if using a less toxic chemotherapy in combination with a drug called imatinib, can effectively treat standard risk Ph+ ALL and standard risk ABL-class fusion positive ALL.
Primary Mediastinal B-cell lymphoma (PMBCL): A study combining nivolumab and chemo-immunotherapy as a treatment option
This study is for children: • 2 years old and older • Received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL)...
This study is for children: • 2 years old and older • Received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) The goal of this study is to compare the effects, good and/or bad, of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone. In this study children will get 1 of 2 treatment plans.
Recurrent or Progressive Low-Grade Glioma: A Study to Compare Treatment with the Drug Selumetinib Alone vs. Selumetinib and Vinblastine
Study participants must be ages 2 through 25 and are suspected of having progressive or recurrent low-grade glioma (LGG). This study looks at how well selumetinib and vinblastine work when given together to children and young adults with recurrent or progressive LGGs. Vinblastine...
Study participants must be ages 2 through 25 and are suspected of having progressive or recurrent low-grade glioma (LGG). This study looks at how well selumetinib and vinblastine work when given together to children and young adults with recurrent or progressive LGGs. Vinblastine is often given to children with progressive or recurrent LGGs. Selumetinib is a drug that works by blocking a protein (a basic building block of the human body) that lets cancer cells grow without stopping. Early studies with selumetinib have had some success in treating patients with LGG that came back after a first attempt at treatment. However, the use of selumetinib in children and young adults with recurrent or progressive LGG is considered experimental because selumetinib has not yet been FDA approved for this type of cancer.